Andreas Jenne

Andreas Jenne has a diverse work experience in the biotechnology and investment industry. Andreas is currently serving as Chairman of the Board at Navignostics AG and NEOsphere Biotechnologies GmbH. At NEOsphere Biotechnologies GmbH, they also held the position of Interim CEO from January 2022 to November 2022. In 2022, they also worked as CEO at Ventura BioMed Investors.

Previously, Andreas served as a Member of the Board of Directors at The BioScience Ventures Group starting from November 2017. From 2016 to 2021, they worked at SciRhom, holding various positions including Board Member, Managing Director, and Chairman of the Board.

In terms of investment experience, Andreas was a Member of the Investment Committee at High-Tech Gründerfonds from September 2017 to September 2022. Andreas was also a Board Member at PreOmics GmbH from January 2017 to January 2022. Additionally, they served as a Member of the Senate Commission for Fundamental Questions of Genetic Research at DFG from December 2017 to November 2020.

Andreas Jenne has also held executive positions in specific companies. Andreas served as CEO at RSP Systems A/S from May 2018 to January 2020, and as Chairman of the Board at OCTIMET Oncology NV from November 2017 to December 2018.

Andreas Jenne pursued their education from 1989 to 1997 at Ludwig-Maximilians-Universität München. During this period, they obtained a degree of Dr. rer. nat. in Chemistry. Prior to their university studies, Andreas attended Staatliches Landschulheim Marquartstein, but no specific degree or field of study is mentioned for this educational experience.